← Back to all signals
RESEARCH PAPER ANALYSIS

Cohort Profile: The Adolescent and Young Adult Tracking Engagement and Management Skills (AYA TEAMS) Longitudinal Cohort of Childhood Cancer Survivors in the United States.

AI interpretation is pending for this paper.

Open original publication →
PMID41728276
JournalmedRxiv : the preprint server for health sciences
Publication Date2026-02-14
Ingested2026-08-02 12:06 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

PURPOSE: To describe the rationale, methods, and baseline sample descriptives of the Adolescent and Young Adult Tracking Engagement and Management Skills (AYA TEAMS) cohort. The AYA TEAMS study is a longitudinal observational cohort study that aims to identify determinants and patterns of self-management and engagement in cancer-related long-term follow-up (LTFU) care and validate a novel transition readiness assessment among adolescent and young adult (AYA) survivors of childhood cancer. PARTICIPANTS: AYA survivors of childhood cancer (ages 16-25) and their caregivers were enrolled from 3 large pediatric oncology centers across the United States from 2020-2022 and followed for 2 years (minimum) to 3 years and 3 months (if transferred to adult care). AYA inclusion criteria were: past childhood cancer diagnosis, at least 2 years off-treatment, 5 years since diagnosis, engaged with the participating pediatric health care system within the last 18 months, cognitively able to complete study procedures, and English speaking. AYA completed a comprehensive battery of measures including assessments of self-management and transition readiness at baseline and annually for 2 years. For AYA transferred to adult care, separate measures were administered at the time of transfer (following last pediatric visit) and 15 months post transfer. Caregivers (English or Spanish-speaking) completed a single survey at baseline to capture family functioning, psychosocial risk, and transition readiness. Cancer diagnosis, treatment modalities, treatment-related late effects, and engagement in LTFU care were captured via electronic medical record review. In total, 709 AYA were enrolled and 587 were included in the final cohort [Mage=19.7 years, 52.5% female, 38.2% from racial and/or ethnic minoritized groups, (REMG)]. The cohort was on average 7.3 years old at the time of diagnosis and 10.5 years off treatment. Half (52.5%) were survivors of leukemia/lymphoma, 38.0% solid tumors, and 9.5% central nervous system tumors. Three hundred and ninety-nine caregivers participated (90% mothers). FINDINGS TO DATE: Enrolled AYA excluded from the baseline cohort were more likely to be male, from REMG, and/or to enroll without a caregiver. Baseline cohort differences between sites emerged for age, race and ethnicity, socioeconomic status, and treatment modalities and intensity. FUTURE PLANS: Data collection was completed in April 2025. Findings from this cohort will elucidate important predictors of self-management and engagement in recommended annual LTFU and inform the design of interventions to reduce disengagement in LTFU.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Comparison of Phenol Application and Endoscopic Pilonidal Sinus Treatment in Pediatric Pilonidal Sinus Disease. Pediatrics international : official journal of the Japan Pediatric Society 63.74 2 Unfinished Business and Experiences of Bereaved Families of Patients with Cancer: A Cross-Sectional Survey. Palliative medicine reports 61.0 3 The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities. Clinical lymphoma, myeloma & leukemia 49.0 4 Acute Leukemia During the First Six Months of Life: A Population-Based Analysis of Survival by Leukemia Type. Clinical lymphoma, myeloma & leukemia 64.12 5 Pediatric orbital solitary fibrous tumor/hemangiopericytoma presenting with isolated eyelid edema: a case report. Frontiers in pediatrics 53.1 6 Malignancies in patients with inborn errors of immunity: insights from 20-years of clinical experience in Qatar. Frontiers in immunology 68.6 7 Precision medicine and parental experience: a longitudinal study of psychosocial responses to germline genomic results in pediatric oncology. Frontiers in medicine 67.36 8 Cytokine-augmented risk stratification for six-month incident nephritis in children with IgA vasculitis. Frontiers in pediatrics 58.5 9 Time-bounded uncertainty in childhood cancer survivorship: a psycho-oncology perspective on result communication. Frontiers in psychology 57.0 10 "From misdiagnosis to precision medicine: strengthening pediatric neuro-oncology care in LMICs toward equitable pLGG outcomes". Frontiers in oncology 75.5 11 Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper. European journal of neurology 66.4 12 Technical Considerations for Robotic Pediatric Lobectomy. Annals of thoracic surgery short reports 54.0 13 Kaposi Sarcoma-Associated Herpesvirus Is Not Detected in Osteosarcoma From KSHV-Endemic African Countries and the Non-Endemic United States Populations. Journal of medical virology 59.5 14 ELISA (Embedding-Linked Interactive Single-cell Agent): an interpretable hybrid generative Artificial Intelligence agent for expression-grounded discovery in single-cell genomics. Briefings in bioinformatics 48.5 15 Thyroid Cancer in the Modern Era: From Molecular Landscape and Multimodal Diagnostics to Integrative Traditional Chinese Medicine-A Comprehensive Review. Cancer management and research 90.6 16 Presumed left atrial myxoma presenting with seizures, massive stroke, and systemic embolization in an adolescent: a case report. International journal of emergency medicine 49.0 17 Ewing's Sarcoma in Adults: A Predictive Nomogram and Survival Analysis of a Cohort of 937 Patients. Journal of surgical oncology 73.92 18 Comments on "Initial Cerebrospinal Fluid Blast Clearance Rate in Pediatric B-Lymphoblastic Leukemia Is Associated With Overall Survival". Journal of pediatric hematology/oncology 49.12 19 Impact of Number of Lymph Nodes Sampled and Density of Positive Nodes on Outcomes Among Over 2000 Patients With Stage I to III Favorable Histology Wilms Tumor Enrolled on AREN03B2: A Children's Oncology Group Renal Tumor Study. Annals of surgery 70.5 20 Prognostic impact of risk organ involvement and metabolic parameters assessed by staging 18F-FDG PET/CT in pediatric Langerhans cell histiocytosis. Nuclear medicine communications 63.3 21 Prognostic value of plasma thymus- and activationregulated chemokine levels after the second cycle of chemotherapy in pediatric Hodgkin lymphoma. Haematologica 55.44 22 Germline lymphoma-predisposing variants: impact on age of cancer diagnosis and survival in pediatric patients. Haematologica 51.12 23 Excess mortality convergence after paediatric allogeneic transplantation: a caveat for the right to be forgotten. Comment on: "Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia". Haematologica 49.5 24 EARLY DISCONTINUATION OF ANTIBIOTICS IN PEDIATRIC PATIENTS WITH LOW- AND HIGH-RISK FEBRILE NEUTROPENIA: A SINGLE-CENTRE EXPERIENCE. Journal of the Pediatric Infectious Diseases Society 68.4 25 Comment on "How I Approach Anxiety in Children and Teens with Cancer". Pediatric blood & cancer 47.5 26 Progressive Tracheal Injury Following Tumor Regression in a Child With T-Cell Lymphoblastic Lymphoma. Pediatric blood & cancer 28.5 27 Very Late Relapse of Acute Myeloid Leukemia With a Rare HNRNPH1::MLLT10 Fusion Following a Pediatric Myeloid Neoplasm: A Successful Venetoclax-Azacitidine Bridge to Hematopoietic Stem Cell Transplantation. Pediatric blood & cancer 49.12 28 Interventions to Reduce Financial Toxicity of Childhood, Adolescent, and Young Adult Cancer Survivors: A Scoping Review. Pediatric blood & cancer 61.32 29 ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T-Cell Lymphoblastic Leukemia/Lymphoma. Pediatric blood & cancer 87.42 30 Advanced Radiotherapy Across a Multi-Geography Referral Network for Children With Ewing Sarcoma and Rhabdomyosarcoma: Treatment Delivery and Early Outcomes-A Single-Centre Experience. Pediatric blood & cancer 72.88 31 Genomic Characterization of ETV6::RUNX1-Positive Childhood B-ALL in a Chinese Cohort: Novel Fusion Partners, Co-Occurring Mutations, and Risk-Stratifying Biomarkers. Pediatric blood & cancer 59.75 32 Diagnostic Yield of Brain MRI in Pediatric Short Stature: Hypothalamic-Pituitary Lesions and Incidental Findings in Real-World Practice. Clinical endocrinology 67.3
PATIENT-FRIENDLY SUMMARY

Cohort Profile: The Adolescent and Young Adult Tracking Engagement and Management Skills (AYA TEAMS) Longitudinal Cohort of Childhood Cancer Survivors in the United States.

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic